PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) today announced that it has received three additional Marketing Authorizations under the European Mutual Recognition Procedure for Loramyc® in Germany, Belgium and Luxemburg (following on from the first authorizations granted in January in the United Kingdom and Denmark).
